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Summary 
Inbred diabetes-prone (DP) BioBreeding/Worcester  (BB/Wor)  (P,.T1 u) rats develop spontane- 
ous autoimmune diabetes, which, like human insulin-dependent  diabetes mellitus, is mediated 
by autoreactive  T  lymphocytes.  Breeding  studies  have shown  an absolute  requirement  for at 
least one copy of the major histocompatibility complex (MHC) RT1 u haplotype for spontane- 
ous  diabetes  expression.  Concanavalin  A-activated  spleen  cells from acutely diabetic  DP  rats 
adoptively transfer diabetes only to recipients that express at least one RT1 u haplotype. To in- 
vestigate the basis for the MHC  requirement  in BB/Wor  autoimmunity,  diabetes-inducing  T 
cell lines were  derived  from the spleens of acutely diabetic  DP  rats.  Upon activation in vitro 
with islet cells, the T  cell lines adoptively transfer insulitis and diabetes into young DP recipi- 
ents  and  non-diabetes-prone  RT1  congenic  rat  strains  that  are  class  II  u.  Recipients  that  are 
tLT1 u at only the class I A  or C  locus, but not at the class II B/D loci, do not develop diabetes 
after T  cell transfer. The adoptive transfer of diabetes by Concanavalin A-activated diabetic DP 
spleen cells also requires that donor and recipient share class  II B/D u gene products.  Further- 
more, the adoptive transfer of diabetes into MHC  class  II  u congenic rats is independent  of the 
class  I  haplotype;  i.e.,  it occurs in the presence  of class  I A a C u or A u C a gene products.  BB/ 
Wor T  cells can be activated in vitro for the transfer of diabetes with islet cell antigens and class 
II-positive but not class IP-negative antigen-presenting  cells. The inductive phase of BB dia- 
betes is therefore MHC  class II restricted,  and this appears to operate at the level of interaction 
between  inducing  T  cells and  class II  u antigen-presenting  cells.  These results may explain  the 
well-documented,  but  not yet understood,  MHC  class  II genetic  contribution  to insulin-de- 
pendent  diabetes mellitus  pathogenesis,  and  they may facilitate the  development  of protocols 
designed to prevent diabetes onset in susceptible individuals. 
D 
iabetes-prone  (DP) 1  BioBreeding/Worcester  (BB/ 
Wor)  rats develop spontaneous  autoimmune  diabetes, 
in which the frequency of insulin-dependent,  ketosis-prone 
hyperglycemia is 80-95% in both sexes. BB diabetes is char- 
acterized morphologically by a  [3 cell-specific mononuclear 
cell infiltrate (insulitis) within the pancreatic islets of Langer- 
hans.  The autoimmune  attack selectively destroys the insu- 
lin-producing [3 cells, with sparing of glucagon-, somatosta- 
tin-,  and pancreatic  polypeptide-synthesizing  islet cells  (1). 
These clinical features of BB diabetes are identical to those 
of human insulin-dependent  diabetes mellitus (IDDM)  (2). 
BB/Wor  rat diabetes  is T  cell  dependent;  the  develop- 
ment  of hyperglycemia is prevented  by neonatal  thymec- 
tomy (3)  and in vivo treatment with mAbs directed against 
CD5 +  (pan T) or CD8 +  (cytotoxic) T  cells (4).  Spontane- 
1Abbreviations used in this paper: BB/Wor, BioBreeding/Worcester; CAS, 
Con A-activated Lewis rat splenocytes; DP, diabetes prone; DR, diabetes 
resistant; IDDM, insulin-dependent diabetes meUitus; NOD, nonobese 
diabetic; SEE, staphylococcal enterotoxin E. 
ous BB diabetes is an MHC-linked  disease. Breeding stud- 
ies  have  shown  an  absolute  requirement  for  at  least  one 
copy of the  MHC  RT1 u haplotype  for the  appearance  of 
spontaneous  diabetes  in  crosses between  BB  and  non-BB 
strains of rat (5-7). Genetic susceptibility, however, has not 
been previously assigned to single genes of the MHC,  nor 
have the immune effector mechanisms leading to [3 cell de- 
struction  been  identified  as  being  class  I-  or  class  II-re- 
stricted events. 
BB/Wor  diabetes  can  be  adoptively  transferred  with 
acutely diabetic DP spleen cells that have been activated in 
vitro with  Con  A,  a  polyclonal  mitogen  (8),  or staphylo- 
coccal  enterotoxin  E  (SEE;  Toxin  Technology,  Sarasota, 
FL)  (9), a T  cell receptor V[3 family-specific stimulus  (10). 
Adoptive  transfer has been  demonstrated  using young DP 
(8), cyclophosphamide-treated  histocompatible RT1 u non- 
BB  (11)  or  athymic  nude  RT1 u  rats  (12)  as  recipients. 
Transfer studies using young DP recipients have implicated 
both the CD4 +  (13) and CD8 +  (14) T  cell subsets as being 
necessary for adoptive transfer.  Since DP recipients possess 
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cells, these studies do not permit a precise determination of 
the  cell type required for initiating the  diabetogenic pro- 
cess. Experiments designed to discriminate between induc- 
tive versus effector events and to map each arm of the dia- 
betogenic immune response to a specific MHC locus would 
require the use ofnon-BB, non-diabetes-prone ILT1 u class 
I or class II congenic recipients in adoptive transfer studies. 
In non-BB P,.T1 u congenic recipients, one can measure de 
novo  disease  induction rather  than  the  acceleration  of a 
spontaneous disorder that would eventually occur in diabe- 
tes-prone BB recipients. 
To investigate the basis for the MHC requirement in BB 
autoimmune diabetes,  diabetes-inducing T  cell lines were 
generated from the spleens of acutely diabetic DP rats.  The 
diabetes transfer capabilities of the T  cell lines were tested 
in syngeneic and class I or class II congenic non-diabetes- 
prone recipients. The ability of class I  or class II congenic 
APC to activate the T  cells in vitro for the adoptive transfer 
of diabetes in vivo was also assessed.  The results presented 
herein explain, at least in part, the MHC genetic contribu- 
tion to IDDM pathogenesis in the rat and shed light on the 
pathogenesis of [3 cell destruction. 
Materials and Methods 
Animals.  BB/Wor DP and BB/Wor diabetes-resistant  (DR.) 
rats and inbred PVG.IL8, PVG.I~3, LEW1.AK2, and LEW1.WtL1 
rats were raised at the University of Massachusetts Medical  Cen- 
ter (Worcester,  MA)  under viral antibody-free conditions. Viral 
antibody-free LEW1.AtL2 and LEW1.WIL1  breeding stock were 
obtained from the Central Institute for Laboratory Animal Breed- 
ing (Hannover, Germany). 
Islet Cell Preparation.  Islets  were isolated from 90-d DIL rats 
by the method ofGotoh et al. (15). Pancreatic tissue was digested 
with 4 mg/ml collagenase P (Boehringer Mannheim Corp., Indi- 
anapolis, IN) for 25 min at 37~  Islets were enriched on Histo- 
paque 1077  (Sigma Chemical Co., St. Louis,  MO)  (1,800  rpm, 
30 rain, 4~  and purified by handpicking under a microscope. 
Islets were dispersed in trypsin/EDTA {12 min at 37~  and im- 
mediately cryopreserved  in 10% DMSO/45% ILPMI  1640/45% 
FCS. Freshly thawed islet cells were "/irradiated (3,000 IL) before 
use. To deplete residual islet-associated APC, freshly thawed islet 
cells at 106/ml were sonicated 2 ￿  20 s on ice with an ultrasoni- 
cator (Microson; Heat Systems Inc., Farmingdale,  NY). 
Generation of T  Cell Lines.  Spleens were taken from acutely 
diabetic  DP rats (duration of diabetes  <5 d), processed  into sin- 
gle-cell suspensions, allowed to adhere  to plastic for 2 h at 37~ 
and plated  at 6  ￿  106 nonadherent cells/ml in 1LPMI 1640, 2% 
autologous rat serum,  and 2 ~zg/ml SEE at 37~  in 6.5% CO2. 
After 3 d, the activated blasts were purified on Histopaque 1077 
(2,000 rpm, 20 min, 22~  and plated at 105/ml in tLPMI 1640, 
10% heat-inactivated FCS  (Hyclone Laboratories,  Logan,  UT), 
and 5% supematant from 48-h Con A-activated Lewis rat spleno- 
cytes (CAS). After two to three passages in CAS,  the cells were 
restimulated for 3 d at 4 ￿  10S/ml with whole 3,000-R irradiated 
DR islet cells (freshly thawed after cryopreservation),  5% CAS, 
and 1.25 ￿  106/ml irradiated nonadherent DP spleen cells (3,000 
IL)  in ILPMI  1640,  1% autologous rat serum.  The ratio  of islet 
cells to  T  cells was ,'~1:22. Antigen-activated blasts were again 
purified on Histopaque 1077 (2,000 rpm,  15 rain, 22~  plated 
at 105/ml in 10% CAS, and passaged several times before restimu- 
lation with antigen (islet cells or SEE) and APC. Culture medium 
consisted  of  ILPMI  1640,  1  mM  sodium  pyruvate,  2  mM 
glutamine, 10 mM Hepes,  5  ￿  10  -5 M  2-ME, and 1￿  antibi- 
otic/antimycotic  (GIBCO  BILL, Gaithersburg,  MD).  Before 
adoptive transfer, T cell lines were activated for 3 d with antigen 
and APC. Blast-transformed  cells were harvested  on Histopaque 
1077 and cultured for a further 2 d in 10% CAS.  ILesting (un- 
stimulated)  T  cells were  transferred  after  two  passages in  10% 
CAS. 
Adoptive Transfer of T Cell Lines into DP Rats.  T cells were in- 
jected intraperitoneally  into 21-28-d female DP rats, which were 
monitored for 21  d after transfer for the development of glycos- 
uria (TesTape; Eli Lilly and Co., Indianapolis,  IN) and hypergly- 
cemia (blood glucose ->13.8 retool/liter; Beckman Glucose Ana- 
lyzer  II; Beckman Instruments, Inc., Fullerton, CA).  The mean 
age at onset of spontaneous diabetes in the University of Massa- 
chusetts  Medical Center DP colony is 75 d for females with an 
incidence of 0.04% at 45 d of age. Hyperglycemia detected before 
45 d of age was considered to be the result of the injected T cells. 
Diabetic rats were killed on the day of detection, and nondiabetic 
rats at 21 d after transfer. 
Adoptive Transfer of T Cell Lines into RTI" Congenic Rats.  Islet 
cell-activated T cells were injected intraperitoneally  into 21-30-d 
male  and female  congenic rats treated  24  h  earlier  with cyclo- 
phosphamide (Cytoxan; Mead Johnson Laboratories,  Princeton, 
NJ),  180 mg/kg body weight i.p. ILats were monitored for 21  d 
for the development of glycosuria and hyperglycemia (blood glu- 
cose -->13.8 mmol/liter). 
Con A  Activation of Acutely Diabetic DP Spleen Cells.  Spleens 
were taken from acutely diabetic DP rats (duration of disease <5 
d), processed into single-cell suspensions, and cultured at 5 ￿  106 
ceUs/ml in RPMI 1640,  2 mM glutamine, 10 mM Hepes,  5  X 
10 -5 M 2-ME, 5% FCS, and 4 I.Lg/ml Con A (ICN Biomedicals, 
Inc., Costa Mesa, CA) for 3 d at 37~  6.5% CO  2. Activated cells 
were  washed  four times in ILPMI  1640  before  injection. One 
spleen equivalent of Con A-activated cells was injected intraperi- 
toneally into recipient rats. 
Morphologic  Studies.  Pancreata  and  thyroids  were  fixed  in 
Bouin's solution and  embedded  in  paraffin.  Hematoxylin and 
eosin stained sections were examined for the presence  of insulitis 
and thyroiditis.  Selected sections were immunostained for insulin 
and glucagon (16) to evaluate the selective destruction of pancre- 
atic oL and [3 cells. 
mAbs.  OX-8 (anti-CD8)  (17) and W3/25 (18, 19) (anti-CD4) 
mAbs were produced by hybridoma cell lines from Dr. A. Will- 
iams and Dr. D. Mason (Oxford University, Oxford, UK). The 
3.2.3  hybridoma was  obtained from J.  C.  Hiserodt.  The 3.2.3 
mAb recognizes  rat NK cells and selectively depletes NK cells in 
vivo (20, 21). Undiluted tissue culture supernatants were used for 
flow cytometry as previously described  (4). 
Results 
Generation  and Characterization  of BB /Wor Diabetes-induc- 
ing  T  Cell  Lines.  BB/Wor autoimmune diabetes  can be 
adoptively transferred into syngeneic recipients with acutely 
diabetic DP spleen cells that have been activated in vitro by 
SEE,  a  TC1L V[3  family-specific stimulus (9).  T  cell lines 
were generated from the spleens of acutely diabetic DP rats 
by first culturing them in vitro with SEE. After 3  d,  SEE- 
reactive lymphoblasts ("~9% of input spleen cells)  were en- 
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source ofT cell growth factors. At the second round of an- 
tigen-specific selection, T  cells were stimulated with whole 
BB/Wor islet cells and APC. Islet cell-reactive T  lympho- 
blasts were density gradient purified and passaged further in 
CAS. At the third cycle of antigen activation, T  cells  lines 
were restimulated  with  either  SEE and APC or with  islet 
cells and APC.  This protocol generates  a population  of T 
cells  with  potent  diabetes  transfer  activity.  A  single  intra- 
peritoneal  injection  of  12-34  ￿  106  T  cells  adoptively 
transferred  diabetes  into  21-28-d-old  DP  recipients  in  as 
few as 5  d  after cell injection  (Table  1),  with a mean time 
to hyperglycemia of 7.9  d  (n  =  48).  DP rats also develop 
spontaneous thyroiditis,  although at a low and variable in- 
cidence  (22).  Diabetic  recipients  of T  cell lines,  however, 
did  not develop  thyroiditis  (n  =  48).  Hyperglycemia was 
always accompanied by a 13 cell-destructive insulitis. 
Only antigen-activated T  cells transfer disease;  unstimu- 
lated (resting) T  cells transferred  >5 d  after antigen activa- 
tion (with islet cells or SEE) did not induce adoptive diabe- 
tes  (Table  1,  line  4)  or  insulitis.  By  single-color  flow 
cytometry, the cell lines were comprised (at all time points 
tested)  of 70-90% CD4 + and  10-30% CD8 + T  cells  (data 
not shown). Although DP rats have low, barely measurable 
levels  of CD8+/CD5 +  CTLs  and  increased  numbers  of 
CD8+/CD5-/3.2.3 + NK cells (23, 24), the T  cell lines did 
not contain 3.2.3 + NK cells at any time. The cell lines pro- 
liferate in vitro in response to both islet cells and SEE (data 
not  shown).  One  cell  line  (A91-1),  also  derived  from 
acutely diabetic DP spleens,  was initially selected and then 
repetitively  stimulated  in  vitro  with  whole  islet  cells  and 
APC, but it did not transfer diabetes or insulitis into any of 
28 DP recipients  (21-25 d  old) given  19-57  X  106 T  cells 
(data not shown).  The initial  in vitro activation step  with 
SEE appears to select for T  cells with both islet cell reactiv- 
ity and diabetes transfer capabilities. 
Adoptive Transfer of T  Cell Line-mediated Diabetes  is MHC 
Class II" Restricted and Independent of Class I Haplotype.  To 
exclude the possibility that the T  cell lines were simply ac- 
celerating or costimulating an endogenous immune process 
genetically present in DP recipients, T  cell lines were trans- 
ferred  into  ILT1  congenic  non-BB  strains  of rat.  These 
congenics contain non-BB RT1 u genes,  in different allelic 
combinations on the genetic background of parental Lewis 
(RT11)  and  PVG  (ILT1 c)  strains.  Neither  the  I~T1 u con- 
genics nor their parental  strains spontaneously develop in- 
sulitis or diabetes.  To prepare congenic rats for BB/Wor T 
cell injections,  recipients were treated with cyclophospha- 
mide  24  h  before  transfer.  Cyclophosphamide depletes  T 
cells and enables RT1 congenic rats to accept the BB/Wor 
T  cells,  with which they share only partial genetic identity 
(11). Cyclophosphamide alone does not induce diabetes or 
insulitis in RT1 congenic rats (see Table 3). 
Islet cell-activated T  cell lines injected into PVG.R8 rats 
induced  diabetes  and  insulitis  in  14  out  of 17  recipients, 
with a mean time to hyperglycemia of 7.4 d  (Tables 2 and 
3).  Pancreatic tissue sections taken from diabetic  and con- 
trol cyclophosphamide-treated PVG.R8 rats were immun- 
ostained for the localization of islet cell peptide hormones. 
Islets of Langerhans from diabetic rats exhibited destructive 
lymphocytic insulitis with depletion of insulin-producing 13 
cells  and  sparing  of glucagon-producing ot cells  (Fig.  1  C 
and D) and somatostatin-producing 5 cells (data not shown). 
Cyclophosphamide-treated  rats  revealed  no  insulitis  and 
had  normal  numbers  and  distributions  of or,  [5  (Fig.  1,  A 
and  B),  and  8  cells.  Islet  cell-activated  T  cells  also  trans- 
ferred diabetes and insulitis  into 9 out of 10 LEW1.WR1 rats 
(Table 3), with a mean time to hyperglycemia of 9.7 d and 
a mean blood glucose of 20.4 retool/liter.  Thus, BB/Wor 
islet cell-activated T  cell lines have an in vivo specificity for 
insulin-producing  13  cells,  even  when  transferred  into  a 
non-BB genetic environment. 
When  islet  cell-activated  T  cells  were  transferred  into 
PVG.R23 recipients, none of the rats developed insulitis or 
diabetes  (Table  3).  T  cells  from the lines used in these ex- 
periments  (at the same or a later passage) transferred diabe- 
Table 1.  BB/Wor Diabetes-inducing T Cell Lines 
Incidence  Mean time  Mean blood 
Cell line  of diabetes  Stimulus  Cell No.  to diabetes  glucose 
>(  106  d  mmol/liter 
BF-1  6/6  Islet cells  16-20  7  26.4 
BF-1  3/3  SEE  32  5  25.0 
BB-3  4/4  Islet cells  19  6  19.8 
BB-3  0/4  None  22  --  -- 
BB-3  2/2  Islet cells  12  8  15.7 
BB-5  3/3  SEE  34  12  28.9 
J193  2/3  Islet cells  17  7  27.9 
T cell lines were activated for 3 d with islet cells/APC or SEE/APC as described in Materials and Methods. Blast-transformed cells were harvested 
on Histopaque 1077 and cultured for a further 2 d in 10% CAS. Resting T cells (no stimulus) were transferred after 2 passages in CAS. T cells were 
injected intraperitoneally into 21-28 d female DP rates. Recipients were monitored for 21 d for the development of hyperglycemia (blood glucose 
>-13.8 retool/liter). A total of 45 out of 48 DP rats injected with T cell lines developed diabetes, with a mean time to hyperglycemia of 7.9 d. 
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Islet Cell-activated BB/Wor T  Cell Lines 
Incidence  Mean time  Mean blood 
Cell line  Cell No.  of diabetes  to diabetes  glucose 
X  I06  d  mmol/liter 
Ju92  31  3/4  7  23.8 
BB-5  39  6/6  7.5  25.2 
092  16  3/4  8  17.9 
092  29  2/3  7  24.6 
T cell lines were activated for 3 d with islet cells and APC as described 
in Materials and Methods.  Blast-transformed  ceils were harvested  on 
Histopaque  1077 and cultured for a further 2 d in 10% CAS. T  cells 
were  injected  intraperitoneaUy  into  21-30-d  female  PVG.R8  rats 
treated 24 h earlier with cyclophosphamide,  180 mg/kg body weight. 
None of eight  female PVG.R8 rats given 180 mg/kg cyclophospha- 
mide alone developed diabetes or insulitis. All rats were monitored for 
21 d for the development ofglycosuria and hyperglycemia  (blood glu- 
cose -----13.8  mmol/liter). 
tes  into  9  out  of  10  DP  recipients  and  six  out  of  six 
PVG.R8  rats,  confirming their in vivo diabetogenicity. Is- 
let cell-activated T  cells injected into LEW1.AR2  rats did 
not induce  diabetes  or insulitis in seven recipients  (Table 
3), even though the same line concurrently transferred dia- 
betes into two out of two rats given 18  X  106 T  cells, with 
a  mean  time  to  hyperglycemia  of 8  d  (data  not  shown). 
There were no signs of GVHD in PVG.R23 or LEW1.AR2 
recipients. 
The  combined  data  from  Tables  2  and  3  demonstrate 
that  donor  and  recipient  must  share  class  II  RT1 ~  gene 
products  for  the  successful  transfer  of BB/Wor  diabetes. 
R.T1 ~ congenicity at only the class I RT1A  or RTIC  locus 
is not sufficient for T  cell-mediated transfer of diabetes. Of 
importance is the  observation that  the  adoptive  transfer of 
autoimmune diabetes  into  class  IP  congenic  rats  is  inde- 
pendent of the  class I  haplotype;  i.e.,  diabetes transfer oc- 
curs in the  presence  of class  I  A a C ~ (PVG.R8)  or  A u C ~ 
(LEW1.WR1)  gene products. 
Adoptive  Transfer  of Diabetes  by  Con  A-activated  Acutely 
Diabetic DP Spleen  Cells Also Requires that Donor and Recipi- 
ent Share  Class II  u Gene Products.  To  confirm the in vivo 
MHC  restriction pattern  obtained with  islet cell-activated 
T  cell lines,  Con  A-activated acutely  diabetic  DP  spleen 
cells were also injected into cyclophosphamide-treated RT1 
congenic rats.  One  spleen  equivalent of Con  A-activated 
cells  transferred  diabetes  and  insulitis  into  PVG.R8  and 
LEW1.WR1  but not PVG.R23  and LEW1.AR2  rats (Ta- 
ble 4).  13  out of 14 LEW1.AR2  recipients developed ful- 
minant GVHD  (manifested by wasting,  anemia, and mas- 
sive splenomegaly) 10 d after transfer. Two out of three DP 
rats concurrently receiving the same Con A-activated spleen 
cells  developed  diabetes  at  10-11  d  after  transfer.  Thus, 
cells with  diabetogenic  potential  survived in  LEW1.AR2 
recipients, but without inducing hyperglycemia or insulitis. 
As assessed by adoptive transfer, the cognitive or induc- 
tive  phase  of BB  diabetes  is  MHC  class  II  u restricted  and 
can proceed in the presence of either class I A ~ or C ~ gene 
products.  Thus, the induction of transferred diabetes is de- 
pendent first upon CD4 +  T  cell recognition of f3  cell au- 
toantigen in the context of class II  u in recipient target tissue 
(islet of Langerhans). These  experiments do not, however, 
rule  out a  role  for  CD8 +  CTL  in the  autoimmune attack 
leading to [3 cell destruction. 
Class IP Restriction  of BB Diabetes  Operates  at the Level of 
Interaction  between  Inducing  T  Cells and APC.  To  examine 
the APC as a potential locus for the class II  u restriction, BB 
T  cell lines were activated in parallel with sonicated BB is- 
let cells and BB  or RT1  congenic APC  (irradiated  spleen 
Table 3.  Adoptive  Transfer of Diabetes into MHC Congenic Rat 
Strains by Islet Cell-activated BB/Wor T  Cell Lines 
RT1  Incidence of  Incidence of 
Strain  haplotype  Cell No.  diabetes  insulitis 
>(  106 
PVG.R8  A~B/D"C  u  16-39  14/17  14/17 
PVG.R8  AaB/DUC  u  0  0/8  0/8 
PVG.R23  AuB/D~C  ~vl  27-36  0/14  0/14 
PVG.R23  AuB/DaCavl  0  0/11  0/11 
LEW1.AR2  A~B/DaC  u  36  0/7  0/7 
LEW1.AR2  A~B/DaC  u  0  0/10  0/10 
LEW1.WR1  AuB/D~C~  28  9/10  9/10 
LEW1,WR1  AuB/D~Ca  0  0/7  0/7 
21-30-d-old male and female RT1  congenic rats received  cyclophos- 
phamide,  180 mg/kg body weight intraperitoneally,  24 h before  cell 
transfer.  Control  rats received  cyclophosphamide  alone.  Rats  were 
monitored for 21  d for  glycosuria and hyperglycemia  (blood  glucose 
-> 13.8 mmol/liter). 
Table 4.  Adoptive  Transfer of Diabetes into MHC Congenic Rat 
Strains by Con A-activated Spleen Cells from Acutely Diabetic 
Diabetes-prone BB/Wor Rats 
RT1 
Strain  haplotype  Diabetes  Insulitis 
PVG.R8  AaB/DuCu  19/23  21/23 
PVG.R23  AuB/DaC  "vl  0/17  0/17 
LEW 1 .AR2  A~B/D~C  u  0/14  0/11 
LEW1 .WR1  AuB/DuC~  5/5  5/5 
BB/Wor DP  AuB/DuC  u  24/27  25/27 
Recipients were 21-30-d-old rats of both sexes. Each rat received one 
spleen equivalent of Con A-activated acutely diabetic DP spleen cells 
intraperitoneally  or intravenously.  Congenic rats received  cyclophos- 
phamide, 150-I80 mg/kg body weight i.p., 24 h before spleen cell in- 
jections. For each experiment, cells were concurrently transferred into 
both congenic and BB rats. Recipients were monitored for 3 wk (BB 
rats) or 4 wk  (congenic  rats) for  the development of hyperglycemia 
(blood glucose -> 13.8 mmol/liter). 
926  Induction of BB Diabetes ls Class II Restricted Figure  1.  Photomicrographs show adjacent pancreatic islet sections taken from PVG.I~8 rats treated with cyclophosphanfide alone (A,  B) or cyclo- 
phosphamide followed 24 h later by an injection of islet cell-activated BB/Wor T  cells (C, D). Tissues were fixed in Bouin's solution, and an immuno- 
peroxidase technique was used for identification of  insulin (A, C) and glucagon (B, D). The islets of  cyclophosphamide control (A,/3) reveal no evidence 
ofinsulitis. Insulin-positive [3 cells (A) and surrounding glucagon-positive ix cells (/3) are normal in appearance. The islets of  the diabetic rat reveal an in- 
traislet mononuclear cell infiltrate with almost complete destruction of  the pancreatic ~3 cells (C). Peripheral glucagon-positive ix cells (D) are preserved in 
the diabetic PBV.R8 rats. A and B,  ￿  C and D,  ￿ 
cells).  The  sonication  step was  added  to  deplete  the  islet 
cells of intact class II  § APCs of  BB origin, as such cells are a 
normal component of the islets of Langerhans. After activa- 
tion,  equal numbers of T  cells were injected into 21-25-d 
DP  recipients,  which  were  monitored  for hyperglycemia 
for  15  d  after cell injection.  BB  T  cells  activated in  vitro 
with  islet  cell  antigens  and  BB,  PVG.R8  (B/D"),  or 
LEW1.WR1  (B/D")  APC,  but  not  PVG.R23  (B/D  a)  or 
LEW1.AP,.2  (B/D  a)  APC,  adoptively transferred  diabetes 
(Table 5).  Thus, BB diabetes-inducing T  cells  are class IP 
restricted both in vivo and in vitro. The class II restriction 
appears to  operate at the level of the  interaction  between 
inducing T  cells and class II  u APC. 
Discussion 
BB autoimmune diabetes is an MHC-linked disease with 
a  requirement  for both  CD4 +  (13)  and  CD8 +  (4,  14)  T 
cells.  To  investigate the  basis  for the  MHC  requirement, 
diabetes-inducing  T  cell  lines  were  generated  from  the 
spleens of acutely diabetic DP rats.  When activated in vitro 
with whole islet cells and APC, the T  cell lines have potent 
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diabetes  transfer activity,  wherein  a  single  injection  of T 
cells  adoptively  transferred  hyperglycemia into  21-28-d- 
old DP recipients in as few as 5 d after injection. Hypergly- 
cemia was always accompanied by a [3 cell-destructive in- 
sulitis  with  sparing  of the  glucagon-  and  somatostatin-se- 
creting  islet  cells.  Although  DP  rats  may  also  develop 
spontaneous  thyroiditis  (22),  diabetic  recipients  of T  cell 
lines  never manifested any signs  of intrathyroid  lympho- 
cytic infiltrates. Interestingly, the T  cell lines can also be ac- 
tivated  for  diabetes  transfer  with  the  superantigen,  SEE. 
The ability of a superantigen to activate diabetes-inducing 
T  cells is reminiscent of a recent report suggesting a role for 
superantigen in human IDDM etiology (25). 
To determine which type ofT cell initiates the develop- 
ment of diabetes, BB/Wor T  cell lines were injected into 
non-diabetes-prone RT1 u class I or class II congenic recip- 
ients.  Upon  islet  cell  activation  in  vitro,  the  T  cell lines 
rapidly transferred insulitis  and diabetes into  class  IP con- 
genic rats. Recipients that are RT1 u at only the class I A or 
C  locus,  but not at the  class II B/D loci, did not develop 
diabetes after T  cell  transfer.  The adoptive transfer of dia- Table 5.  BB/Wor Diabetes-inducing  T  Cells Require Activation 
with MHC Class II"-positive APC and Islet Cell Antigens for 
Disease Transfer 
Experiment  Source  Class II  Incidence  Mean time 
No.  of APC  loci  of diabetes  to diabetes 
d 
1  BB/Wor  B/D  u  7/8  11 
PVG.R.23  B/D a  0/8  -- 
2  BB/Wor  B/D  u  6/7  9 
LEW1.WR1  B/D u  4/5  10 
3  BB/Wor  B/D u  7/8  9 
PVG.R.8  B/D  u  8/9  9 
4  PVG.P,.8  B/D  u  1/2  11 
LEW1.AI<2  B/D  ~  0/3  -- 
5  BB/Wor  B/D  u  4/4  12 
LEW1.AP,2  B/D  ~  0/2  -- 
BB/Wor T  cells (4  ￿  10S/ml) were  activated in parallel with DP or 
RT1  congenic 3,000-R spleen cells (2 ￿  106/ml), 5% FCS, 5% CAS, 
and sonicated BB islet cells. The sonicates were always checked micro- 
scopically for the absence of whole cells. Islet cell sonicates were used at 
a ratio of 1 cell equivalent per 21  T  cells. After 3 d, blasts were har- 
vested on Histopaque  1077 and cultured for 2 d in 10% CAS. Equal 
numbers of T cells (usually 25  ￿  106) were then injected intraperito- 
neally into 21-25-d female DP rats, which were monitored for 15 d for 
the  development  of glycosuria  and  hyperglycemia  (blood  glucose 
---  13.8 mmol/liter). 
betes by Con A-activated, acutely diabetic DP spleen cells 
also requires that  donor  and  recipient share  class II B/D u 
gene products. Therefore,  the induction of BB  diabetes is 
restricted by class II  u gene products and is CD4 + T  cell me- 
diated. Of importance is the fact that the adoptive transfer 
of diabetes into class IP congenic rats is independent of the 
class I haplotype; i.e., it occurred in the presence of class I 
A a C u (PVG.RS) or A u C a (LEW1.W1L1) gene products. In 
contrast, the adoptive transfer of antiviral cytotoxic CD8 + 
T  cell effector activity is restricted by recipient class I, but 
not class II, genes (26). 
These data are surprising, because, in the rat, the insulin- 
producing  13  cell targets  do  not  express  detectable MHC 
class  II  gene  products  in  vivo  (27-29),  even  during  the 
course of spontaneous BB/Wor  insulitis and diabetes (30). 
BB rat 13 cells do, however, express class I products in vivo, 
with  class I  hyperexpression and infiltrating CD8 +  T  cells 
being  invariant  concomitants  of the  autoimmune  attack 
(24, 28, 31).  It is likely that 13 cells in situ shed or secrete a 
protein that is taken up by class II  +  intraislet APC, which 
process and then present antigen to 13 ceil peptide-specific 
CD4 + T  cells in a class II-restricted manner.  The activated 
CD4 +  T  cells would,  in turn,  activate 13 cell peptide-spe- 
cific CD8 + T  cells, which would serve as the final effectors 
of [~ cell cytolysis. CD8 + T  cells are known to be critically 
important  in  BB  diabetes.  Anti-CD8  mAb  treatment  re- 
moves CD8 +  CTL and decreases the incidence of sponta- 
neous BB  diabetes (4,  24).  In vitro-activated acutely dia- 
betic BB spleen cells, when depleted of CD8 + cells, do not 
adoptively transfer  disease into  CD8-depleted  DP  recipi- 
ents (14).  CD8+/3.2.3 + NK cells are not the final effectors 
of 13 cell cytolysis, because 3.2.3 mAb treatment of DP rats 
removes NK cells but does not reduce the frequency of BB 
diabetes (24). 
Although  the  induction  of BB  diabetes  is  clearly  an 
MHC  class II-restricted CD4 + T  cell-mediated event, the 
data do not rule out a role for CD8 +  CTL as the final el- 
lectors of 13 cell destruction. In the case of the diabetes-in- 
ducing T  cell lines described above, it has not been shown 
that  the  transferred  CD8 +  T  cells actually play a  role  in 
adoptive  diabetes.  It  is  possible  that  the  CD4 +  T  cells 
(which  make  up  70-90%  of the  diabetes-inducing T  cell 
lines) are recruiting 13 cell---specific  CD8 + CTL from within 
the recipient T  cell compartment. Alternatively, the trans- 
ferred CD4 + T  cells may be homing to the islets of Langer- 
hans  and  inducing  the  production  of inflammatory cyto- 
kines  in  situ that  ultimately lead to  [3  cell cytosis  (32).  A 
formal demonstration of a role for CD8 +  CTL in BB dia- 
betes would depend upon the ability of islet cell-activated 
CD8 + T  ceils to adoptively transfer insulitis and hypergly- 
cemia into  class I u congenic recipients, irrespective of the 
animals' class II haplotype. Finally, ifCD8 + CTL are the fi- 
nal  effectors  of 13  cell  cytolysis, then  the  data  presented 
above suggest that they can recognize 13 cell autoantigen in the 
context of either class I A u (LEW1.WR1) or C u (PVG.IL8) 
gene products. 
In  the  nonobese  diabetic  (NOD)  mouse  model  of 
IDDM, both CD4 + and CD8 + spleen cell populations are 
also required for the transfer of diabetes into young NOD 
(33-35)  or NOD-scid/scid recipients  (36).  However,  the 
matter has not been further clarified by transferring spleen 
cells into  other inbred strains  of mice  that  are  class I  (H- 
2K~D b)  or  class  II  (NOR/Lt  [37],  B10.H-2g  7  [38])  con- 
genic with NOD  mice. Diabetes-accelerating CD4 + T  cell 
clones have  been  described in the  NOD  mouse  (39),  but 
their ability to induce (as opposed to accelerate) diabetes in 
non-NOD  MHC  class II congenic recipients has not been 
reported.  Furthermore,  the  acceleration  of  diabetes  in 
NOD  mice  given CD4 +  T  cell clones is effective only if 
the recipients are <19 d of age (40). In contrast, BB T  cells 
efficiently transfer diabetes into 21-30-d-old BB or class II  L' 
congenic recipients. 
The MHC  contains the predominant genetic susceptibil- 
ity factors for IDDM  in humans  (41,  42),  the BB  rat  (7), 
and the NOD  mouse  (43, 44).  In particular, MHC  class II 
genes  are associated with  disease susceptibility in  all three 
species (45-47).  The manner in which the products of the 
IDDM-associated MHC  genes  influence  the  pathogenesis 
of diabetes is still unknown.  The mechanism  could be ei- 
ther  at the level of thymic  T  cell selection or during pe- 
ripheral  immune  response  activation,  both  of which  re- 
quire appropriate peptide presentation by MHC  molecules. 
Our data indicate that, in the BB rat, the MHC  class II ge- 
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by binding of [3  cell peptide to  permissive class II" mole- 
cules,  resulting  in  the  activation  of diabetes-inducing  T 
cells. Specifically, BB  T  cells can be activated in vitro for 
the transfer of diabetes with islet cell antigens and class II  u- 
positive,  but  not  class  IIU-negative, APC  (Table  5).  The 
MHC  class II restriction of BB diabetes thus operates at the 
level of interaction between inducing T  cells and class II  u 
APC. These data lend support to the peptide affinity model 
for the class II genetic contribution to IDDM susceptibility: 
Susceptibility is caused by peptide presentation by a class II 
gene  product that binds diabetogenic peptide, resulting in 
the activation of [3 cell-specific autoreactive T  cells (48). 
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